New research coverage points to a broader immunotherapy shift away from a single “killer T-cell” framing toward more nuanced effector biology. One report described complement footprints being repurposed as a second targeting strike against drug-resistant cancer cells, building on the idea that immune therapy resistance can involve more than antigen escape. A separate review spotlighted macrophage biology as a key mechanism in antibody-driven phagocytosis (ADCP), arguing that macrophages deserve more prominence in how clinicians and developers interpret antibody efficacy. Together, the stories reinforce that next-generation oncology programs may increasingly combine or sequence antibody engineering with strategies that modulate innate immune activity and tumor immune microenvironments.